OR WAIT 15 SECS
CDMO Micro-Sphere is investing CHF 21 million (approximately $21.63 million) into the expansion of its GMP manufacturing capabilities at its Swiss facility.
Micro-Sphere, a CDMO with expertise in spray-drying and capsule filling, announced on Aug. 22, 2017, that it is investing CHF 21 million (approximately $21.63 million) into the expansion of its GMP manufacturing capabilities at its Swiss facility. The GMP production area will be tripled in size following the expansion and will have greater capacity to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms. The expanded facility is expected to be operational by Q4 2017.
“Both GMP spray drying as a particle engineering technique and low-dose capsule filling are becoming increasingly popular across the market and at present there are very few CDMOs offering this level of capability, especially with our level of niche expertise,” Michele Müller, Micro-Sphere founder and president of the board, said in a press statement. “From our expanded facility, we will continue to produce both clinical and commercial products, with a particular specialism in dry powder inhalers. We look forward to unveiling the technologies we will be adding to our facility in the coming months and what I can promise is it will be some of the finest equipment in the world.”
Micro-Sphere supports customers from its FDA-approved facility near Lugano, Ticino in Switzerland. The CDMO offers spray-drying capabilities for the development and manufacture of both potent and non-potent pharmaceutical products, with a particular focus on inhalable dosage forms.